- Document Security Systems Inc's DSS subsidiary, DSS Biomedical International, Inc., has completed a $1 million equity investment in Vivacitas Oncology, Inc.
- Vivacitas Oncology focuses on developing new treatment options to treat cancers resistant to currently available therapies.
- Vivacitas candidate AR-67 is a novel lipophilic camptothecin compound. AR-67 has in vitro, Phase I, and Phase II data in multiple solid tumor types and has shown potential improvement in progression-free survival (6-29 months) in glioblastoma patients while significantly reducing severe side effects usually associated with this drug class.
- Price action: DSS shares traded higher by 1.71% at $1.40 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
